What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms

被引:2
作者
Freeman, Jeffrey S. [1 ]
Horton, Edward S. [2 ]
机构
[1] Philadelphia Coll Osteopath Med, Div Endocrinol & Metab, Philadelphia, PA 19131 USA
[2] Joslin Diabet Ctr, Boston, MA 02215 USA
关键词
type; 2; diabetes; management; efficacy; safety; ADD-ON THERAPY; INADEQUATE GLYCEMIC CONTROL; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; PROTAMINE HAGEDORN INSULIN; INCRETIN-BASED THERAPIES; TWICE-DAILY EXENATIDE; TO-TARGET TRIAL; BASAL INSULIN; DOUBLE-BLIND;
D O I
10.1097/MJT.0b013e31826fc5e5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insulin, the first treatment for diabetes, was discovered >90 years ago. Since then, many new types of insulin have become available, including analogs that more closely mimic the characteristics of endogenous insulin. In addition, oral antidiabetes drugs and other types of injectable therapies have been approved for the treatment of patients with type 2 diabetes. As newer treatments are approved for type 2 diabetes, the choice and-paradoxically-the complexity of treatment increases. The potential benefits of all treatment options must be carefully balanced against potential adverse events to truly analyze the overall efficacy, safety, tolerability, and potential long-term effects. The manner in which outcomes are assessed and the methods employed to make such assessments have changed over time. This review will address these issues as they are related to therapies for type 2 diabetes, including insulin, oral antidiabetes drugs, and incretin-based agents.
引用
收藏
页码:449 / 464
页数:16
相关论文
共 50 条
  • [41] Empagliflozin for the treatment of Type 2 diabetes
    Komala, Muralikrishna Gangadharan
    Mather, Amanda
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (03) : 271 - 279
  • [42] Ertugliflozin for the treatment of type 2 diabetes
    Sharma, R.
    Razdan, K.
    Kuhad, A.
    Kuhad, A.
    DRUGS OF TODAY, 2019, 55 (03) : 167 - 175
  • [43] Dapagliflozin for the treatment of type 2 diabetes
    Abdul-Ghani, Muhammad A.
    DeFronzo, Ralph A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (12) : 1695 - 1703
  • [44] Changing Paradigms of Seat Belt and Air Bag Injuries: What We Have Learned in the Past 3 Decades
    Carter, Patrice R.
    Maker, Vijay K.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (02) : 240 - 252
  • [45] TENELIGLIPTIN FOR THE TREATMENT OF TYPE 2 DIABETES
    Goda, M.
    Kadowaki, T.
    DRUGS OF TODAY, 2013, 49 (10) : 615 - 629
  • [46] Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation
    Yabe, Daisuke
    Seino, Yutaka
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (02) : 249 - 264
  • [47] Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C
    Skolnik, Neil
    Bonnes, Harmony
    Yeh, Helen
    Katz, Arie
    POSTGRADUATE MEDICINE, 2016, 128 (04) : 356 - 363
  • [48] Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
    Kania, Deanna S.
    Gonzalvo, Jasmine D.
    Weber, Zachary A.
    CLINICAL THERAPEUTICS, 2011, 33 (08) : 1005 - 1022
  • [49] Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
    Goldsmith, David
    Dellanna, Frank
    Schiestl, Martin
    Krendyukov, Andriy
    Combe, Christian
    CLINICAL DRUG INVESTIGATION, 2018, 38 (06) : 481 - 490